PMS-PIOGLITAZONE TABLET
País: Canadà
Idioma: anglès
Font: Health Canada
Fitxa tècnica
(SPC)
14-05-2018
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE)
Disponible des:
PHARMASCIENCE INC
Codi ATC:
A10BG03
Designació comuna internacional (DCI):
PIOGLITAZONE
Dosis:
30MG
formulario farmacéutico:
TABLET
Composición:
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 30MG
Vía de administración:
ORAL
Unidades en paquete:
100
tipo de receta:
Prescription
Área terapéutica:
THIAZOLIDINEDIONES
Resumen del producto:
Active ingredient group (AIG) number: 0141541002; AHFS:
Estat d'Autorització:
APPROVED
Data d'autorització:
2007-12-05
Fitxa tècnica
PRODUCT MONOGRAPH
PR
PMS-PIOGLITAZONE
Pioglitazone Hydrochloride Tablets
15 mg, 30 mg, 45 mg
USP
Anti-Diabetic Agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
Date of Revision:
May 14, 2018
www.pharmascience.com
Submission Control No: 215147
_pms-PIOGLITAZONE Product Monograph _
_Page 2 of 46_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
9
DRUG INTERACTIONS
.........................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................
15
OVERDOSAGE
.......................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 17
STORAGE AND STABILITY
.................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATION
.................................................................................
24
CLINICAL TRIALS
..........................................................
Llegiu el document complet
